Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

Author： Jansen Jeroen P.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.28, Iss.4, 2010-04, pp. : 323-344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK

By Adis International Limited  

PharmacoEconomics, Vol. 23, Iss. 7, 2005-01 ,pp. : 743-743

Adis International

Access to resources Recommend Favorite

Etoricoxib and the treatment of ankylosing spondylitis

By Lories Rik J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 12, 2012-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

The safety of celecoxib in ankylosing spondylitis treatment

By Poddubnyy Denis A   Song In-Ho   Sieper Joachim  

Expert Opinion on Drug Safety, Vol. 7, Iss. 4, 2008-07 ,pp. : 401-409

Informa Healthcare

Access to resources Recommend Favorite

Etoricoxib cost effective for ankylosing spondylitis in the UK

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 600, 2010-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials

By Essex Margaret Noyes   Zhang Richard Y   Berger Manuela F   Upadhyay Sameer   Park Peter W  

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 465-477

Informa Healthcare

Access to resources Recommend Favorite